INS and diabetes mellitus: Panova and colleagues used iPSCs from a patient diagnosed with neonatal diabetes mellitus carrying the INS mutation in the second intron (c.188-31G>A) and engineered isogenic CRISPR/Cas9 mutation-corrected cell lines.